Announcements Trials
Browse Landscape

Phase

Phase 2 1

Status

Active not recruiting 1

Sponsor Class

NIH 1

Study Type

Interventional 1

Sponsor

Conditions

Multiple Myeloma 20Lymphoma 17Neoplasm Metastasis 14Leukemia, Myeloid, Acute 12Pancreatic Neoplasms 9Breast Neoplasms 9Ovarian Neoplasms 8Melanoma 8Lung Neoplasms 8Colorectal Neoplasms 8Sarcoma 7Prostatic Neoplasms 7Leukemia, Lymphocytic, Chronic, B-Cell 7Glioma 7Fallopian Tube Neoplasms 7Cholangiocarcinoma 7Neuroblastoma 6Lymphoma, Non-Hodgkin 6Lymphoma, Follicular 6Endometrial Neoplasms 6Lymphoma, Large B-Cell, Diffuse 5Ependymoma 5Burkitt Lymphoma 5Wilms Tumor 4Urinary Bladder Neoplasms 4Triple Negative Breast Neoplasms 4Squamous Cell Carcinoma of Head and Neck 4Rhabdomyosarcoma 4Rhabdoid Tumor 4Neuroectodermal Tumors, Primitive, Peripheral 4

Interventions

atezolizumab 2talazoparib 1Specimen Handling 1Magnetic Resonance Spectroscopy 1LB100 1Etoposide 1Carboplatin 1Biopsy 1

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
Active not recruiting × Extensive Stage Lung Small Cell Carcinoma × Biopsy × Clear all
NCT04334941 2026-06-05

Testing Maintenance Therapy for Small Cell Lung Cancer in Patients With SLFN11 Positive Biomarker

National Cancer Institute (NCI)

Phase 2 Active not recruiting
103 enrolled

Extensive Stage Lung Small Cell Carcinoma

Data powered by HemOnc (CC BY 4.0) Colophon âš¡